StockData
Avalo Therapeutics, Inc. logo

Avalo Therapeutics, Inc. (AVTX) bonds

AVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/30
$7.13−0.24 (-3.26%)

Close on Nov 17, 2026Market cap $382.38MP/E –Yield –

Debt

Borrowings on the balance sheet, Jun 30, 2026

Avalo Therapeutics reports no long-term debt line

Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.

Notes and loans outstanding

As tagged in Avalo Therapeutics's 10-K for the period ended Jun 4, 2021

IssueAmount issued
Horizon & Powerscourt Notes$35.00M

Companies tag their debt differently: some list every note, others group notes by issuance year or by type, so the list may not add up to total debt. Notes that matured before today are hidden. Source: 10-K.

See a number that looks wrong?